BioCryst Pharmaceuticals | BCRX - Ebitda

Stock Price
9.57
Daily Change
-0.11 -1.09%
Monthly
2.85%
Yearly
32.48%
Q2 Forecast
9.30

BioCryst Pharmaceuticals reported $51.7M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
Chugai Pharma JPY 169.01B 12.52B Dec/2025
Daiichi Sankyo JPY 101.6B 22.81B Mar/2025
DBV Technologies USD -33.48M 5.55M Sep/2025
Gilead Sciences USD 4.03B 628M Sep/2025
GlaxoSmithKline GBP 3.36B 179M Sep/2025
Glaxosmithkline GBP 4.75B 1.52B Sep/2025
Incyte USD 414.5M 92.42M Dec/2025
Ionis Pharmaceuticals USD -157.12M 307.36M Sep/2025
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
Neurocrine Biosciences USD 218.4M 28.3M Dec/2025
Novavax USD 19.36M 190.79M Dec/2025
PTC Therapeutics USD 20.63M 53.74M Sep/2025
Regeneron Pharmaceuticals USD 1.92B 261.9M Sep/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Sarepta Therapeutics USD -168.03M 294.45M Sep/2025
Ultragenyx Pharmaceutical USD -156.79M 65.44M Sep/2025
Vertex Pharmaceuticals USD 1.44B 100.4M Sep/2025